Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2008 4
2009 2
2012 1
2013 1
2017 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY. Porkka K, et al. Among authors: smykla r. Blood. 2008 Aug 15;112(4):1005-12. doi: 10.1182/blood-2008-02-140665. Epub 2008 May 13. Blood. 2008. PMID: 18477770 Free article. Clinical Trial.
Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G. Lee FY, et al. Among authors: smykla r. Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Cancer Chemother Pharmacol. 2008. PMID: 18347795 Free article. Review.
Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.
Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A, Kovanen PE, Porkka K, Lee FY, Mustjoki S. Hekim C, et al. Among authors: smykla r. Cancer Immunol Res. 2017 Feb;5(2):157-169. doi: 10.1158/2326-6066.CIR-16-0061-T. Epub 2017 Jan 10. Cancer Immunol Res. 2017. PMID: 28073775 Free article.
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.
Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, Smykla R, Lee FY, Vakkila J, Jalkanen S, Salmi M, Porkka K. Mustjoki S, et al. Among authors: smykla r. Leukemia. 2013 Apr;27(4):914-24. doi: 10.1038/leu.2012.348. Epub 2012 Nov 29. Leukemia. 2013. PMID: 23192016
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R. Lee FY, et al. Among authors: smykla r. Cancer Chemother Pharmacol. 2009 Jan;63(2):201-12. doi: 10.1007/s00280-008-0727-5. Epub 2008 Mar 19. Cancer Chemother Pharmacol. 2009. PMID: 18350296
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY. Luo FR, et al. Among authors: smykla r. Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27. Cancer Chemother Pharmacol. 2008. PMID: 18301894 Free article.
11 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page